BridgeBio Oncology Therapeutics announced that the U.S. Food and Drug Administration has granted Fast‑Track designation to its pan‑KRAS inhibitor BBO‑11818 for the treatment of adult patients with advanced KRAS‑mutant pancreatic ductal adenocarcinoma. The Fast‑Track status is intended to expedite the development and review of drugs that address serious conditions with unmet medical needs, allowing BridgeBio to engage more closely with the FDA and accelerate clinical milestones if the drug demonstrates clinical benefit in its Phase 1 KONQUER‑101 study.
BBO‑11818 is a first‑in‑class pan‑KRAS inhibitor that targets both the active (ON) and inactive (OFF) states of KRAS, giving it activity against the most common KRAS mutations in pancreatic cancer—G12D and G12V. In January 2026, preliminary data from the KONQUER‑101 trial showed a confirmed partial response in a patient with pancreatic cancer, and the company expects updated Phase 1 data in the second half of 2026.
The KONQUER‑101 study is a Phase 1, open‑label, dose‑escalation trial that is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy of BBO‑11818 in patients with KRAS‑mutant solid tumors. The upcoming data release will provide further insight into the drug’s activity profile and inform the next steps in development.
BridgeBio’s pipeline value and competitive positioning are enhanced by this regulatory milestone. The Fast‑Track designation not only signals the FDA’s recognition of the unmet need in KRAS‑mutant pancreatic cancer but also differentiates BBO‑11818 from other KRAS inhibitors that target only the G12C mutation. The company’s strong cash position—$373.7 million at the end of 2025 and a projected runway into 2028—provides the financial stability needed to advance the clinical program and pursue additional development opportunities.
Yong Ben, MD, Chief Medical and Development Officer of BridgeBio, said, "Receiving Fast Track designation from the FDA for BBO‑11818 in KRAS‑mutant pancreatic ductal adenocarcinoma reflects the importance and urgency of accelerating the development of our pan‑KRAS inhibitor in this serious disease." He added, "Pancreatic cancer remains one of the most difficult‑to‑treat malignancies. KRAS mutations are present in the vast majority of cases, yet patients have had few targeted options. This designation will help us collaborate closely with the FDA to advance BBO‑11818 as efficiently as possible for patients who need new options."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.